Combined oral contraceptive pill

As Opill Enhances Women's Reproductive Choices Dr. Mary Jane Minkin Highlights Key Differences Between the Progesterone-Only Opill and Traditional Estrogen-Based Contraceptives “The Pill”

Retrieved on: 
Monday, March 11, 2024
Health, FDA, Consumer, Women, Baby, Maternity, General Health, Pharmaceutical, Mother, Birth, Education, OBGYN, Combined oral contraceptive pill, Condom, Risk, Diabetes, Ovulation, Stroke, History, Sale, News, Fertility, Splenic infarction, Smoke, Perrigo, Woman, OTC, Pill, Cancer, Breast cancer, Safety, Progesterone, MUST, Migraine, Birth control

Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.

Key Points: 
  • Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.
  • "Education is key at this juncture to prevent an increase in unintended pregnancies in the coming months.
  • The Opill, significantly differs from the traditional birth control pill in that it is less effective at preventing ovulation when pills are missed or skipped for any reason.
  • The availability of the Opill OTC, or progesterone-only pill, is wonderful news for those women unable to take estrogen or 'The Pill.'

Prescription of Oral Contraceptives by Licensed Pharmacists in the US

Retrieved on: 
Monday, March 4, 2024
Combined oral contraceptive pill, Pharmacy, Pharmacology, Woman, OCS, ACCP, Pharmacist, Position paper, Risk, Safety, Health, Contraindication, Pharmacokinetics, American College, Birth, Advantage

ASHBURN, Va., March 4, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled "Prescription of Oral Contraceptives by Licensed Pharmacists in the US" .

Key Points: 
  • ASHBURN, Va., March 4, 2024 /PRNewswire/ -- The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled "Prescription of Oral Contraceptives by Licensed Pharmacists in the US" .
  • Oral contraceptives (OCs) provide a highly effective method of contraception if adherence is maintained; OCs have been prescribed in the US and globally for several decades.
  • The American College of Clinical Pharmacology (ACCP) strongly recommends the enactment of an initiative that permits licensed US pharmacists to prescribe OCs on a national basis.
  • This supports OCs as suitable for prescription by licensed pharmacists at a national level.

Polycystic Ovary Syndrome (PCOS) Treatment Markets, 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 20, 2021
Health, Pharmaceutical, CAGR, Growth, Combined oral contraceptive pill, Diabetes, Treatment, Polycystic ovary syndrome, Antiandrogen, PCOS, COVID-19, Polycystic disease, Pharmaceutical industry, Pet, Video game

The "Polycystic Ovary Syndrome (PCOS) Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polycystic Ovary Syndrome (PCOS) Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Global Polycystic Ovary Syndrome (PCOS) Treatment Market to Reach $4.6 Billion by 2027.
  • Amid the COVID-19 crisis, the global market for Polycystic Ovary Syndrome (PCOS) Treatment estimated at US$3.6 Billion in the year 2020, is projected to reach a revised size of US$4.6 Billion by 2027, growing at a CAGR of 3.5% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $981.1 Million, While China is Forecast to Grow at 6.4% CAGR
    The Polycystic Ovary Syndrome (PCOS) Treatment market in the U.S. is estimated at US$981.1 Million in the year 2020.

DGAP-News: APONTIS PHARMA marks further success in the roll-out of Single Pill therapy

Retrieved on: 
Monday, July 12, 2021
Health sciences, Drugs, Health care, Medication, Pharmaceutical industry, Hepatotoxins, Pharmacy, Enones, Progestogens, Polypill, Combined oral contraceptive pill

Ultimately, patients benefit from a Single Pill treatment versus a multi pill regimen.

Key Points: 
  • Ultimately, patients benefit from a Single Pill treatment versus a multi pill regimen.
  • Therefore, the prescribed medication is taken more reliably when the dosage form is limited to a Single Pill.
  • The Single Pill therapy is evidence-based more efficient and ensures a more sustainable treatment success.
  • Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention.

Advisory - One lot of Linessa 21 birth control pills recalled due to missing and mispackaged pills

Retrieved on: 
Sunday, June 20, 2021
Health sciences, Pharmacology, Health care, Packaging, Pharmaceutical industry, Dosage forms, Blister pack, Combined oral contraceptive pill, Pharmacare, Tablet, Pill

Issue:Aspen Pharmacare Canada Inc. is recalling one lot due to missing and mispackaged pills.

Key Points: 
  • Issue:Aspen Pharmacare Canada Inc. is recalling one lot due to missing and mispackaged pills.
  • What to do: If you have a package with missing or mispackaged pills, return it to your pharmacy for a replacement package.
  • Aspen Pharmacare Canada Inc. is recalling one lot (lot 200049, expiry 03/2023) of Linessa 21, a prescription birth control pill, due to missing and mispackaged pills.
  • Some blister packs may be missing pills, may contain more than one tablet in a blister pocket, and may contain pills in the wrong order.

Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets

Retrieved on: 
Thursday, June 3, 2021
Health sciences, Health care, Health, Dosage forms, Pharmacy, Hepatotoxins, Chemical engineering, Pharmaceutical industry, Tablet, Combined oral contraceptive pill, Adherence, Polypill

The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) approval on April 15, 2021.

Key Points: 
  • The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) approval on April 15, 2021.
  • In addition to the original 20 mg strength tablets, XPOVIO is now available in 40 mg, 50 mg, and 60 mg strength tablets.
  • XPOVIO tablets are available in seven different package sizes to help healthcare providers individualize the dosing and administration of XPOVIO based on patient needs.
  • The additional dosage strength tablets may also increase patient compliance by simplifying their treatment regimen and reducing the pill burden experienced by some patients.

HealthLynked Announces 48% Month over Month Growth for Q1 of Female Users of its Oohvie App and Release of Version 2.0 with Expanded Features

Retrieved on: 
Thursday, April 15, 2021
Menstrual cycle, Menstruation, Human reproduction, Combined oral contraceptive pill, Flo, Health, Software

Released in December 2020, the number of Oohvie app users has grown consistently at 48% month-over -month attracting over 6,000 users.

Key Points: 
  • Released in December 2020, the number of Oohvie app users has grown consistently at 48% month-over -month attracting over 6,000 users.
  • Oohvie has steadily increased engagement of women into the HealthLynked network.
  • Now users can quickly start or stop their period, record spotting, and enter weight and sleep data.
  • We have added menstrual flow and birth control pills to the symptoms page, allowing for more detailed information that is shared to the user\'s HealthLynked Profile.

Mayne Pharma launches another generic oral contraceptive

Retrieved on: 
Thursday, March 4, 2021
Combined oral contraceptives, Drugs, Health care, Ethinylestradiol/etonogestrel, Pharmacology, Combined oral contraceptive pill, Birth control pill formulations, Ortho, Estetrol/drospirenone, Generic drug, Ortho Pharmaceutical

This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.

Key Points: 
  • This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.
  • Mayne Pharma's CEO Scott Richards said, "We are very pleased to expand our Women's Health portfolio which now covers ~80% of Obstetrician/Gynaecologist oral contraceptive prescription volumes[1] and includes 24 marketed branded generic contraceptives.
  • Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options.
  • "In addition, Mayne Pharma has four women's health pipeline products pending at the FDA including the novel combined oral contraceptive NEXTSTELLIS (E4/DRSP) and a generic version of NUVARING.

Healthcare Technology Company Emme Closes $2.5M Seed Round And Announces Launch Of Integrated Technology-Enabled Birth Control Solution

Retrieved on: 
Tuesday, August 25, 2020
Health, Articles, Pharmacy, Women's health, Adherence, Clinical pharmacology, Health care quality, Medical terminology, Combined oral contraceptive pill, Emme, Birth control

SAN FRANCISCO, Aug. 25, 2020 /PRNewswire/ --Emme, a healthcare technology company focused on women's health, today announced the launch of the Emme Smart Case, an integrated solution designed to reduce the 9% failure rate of birth control pills.

Key Points: 
  • SAN FRANCISCO, Aug. 25, 2020 /PRNewswire/ --Emme, a healthcare technology company focused on women's health, today announced the launch of the Emme Smart Case, an integrated solution designed to reduce the 9% failure rate of birth control pills.
  • The smart technology device solves the most significant issue with birth control pills women face pill adherence.
  • "Emme is the first company to offer a comprehensive and complete birth control solution," said Christine Aylward, Founder and Managing Partner of Magnetic Ventures.
  • Emme is a healthcare technology company with a mission to put women's health in women's hands, starting with birth control.

U.S. Sen. Ted Cruz (R-TX) & Live Action Founder and President Lila Rose Call on FDA to Pull Abortion Pill

Retrieved on: 
Monday, August 10, 2020
Hormones, RTT, Drugs, Organic compounds, Abortifacients, Antiprogestogens, Mifepristone, Abortion, Lila Rose, Combined oral contraceptive pill, Live action

Live Action, a leading pro-life organization with over 4.6 million followers online, recently launched Abortion Pill Kills, a campaign exposing the history of the pill and the abortion industrys plan to expand the drug.

Key Points: 
  • Live Action, a leading pro-life organization with over 4.6 million followers online, recently launched Abortion Pill Kills, a campaign exposing the history of the pill and the abortion industrys plan to expand the drug.
  • On July 13, 2020, Obama-appointed U.S District Judge Theodore Chuang, blocked the FDA from enforcing the REMS for Mifeprex, suspending the requirement that abortion pill prescribers dispense the pill at an in-person appointment.
  • Live Action President and Founder, Lila Rose made the following statement:
    The abortion pill has ended the lives of at least 3.7 million innocent children in the U.S. alone.
  • Live Action is a national nonprofit organization dedicated to exposing the truth about abortion and affirming the life of every child.